Clarus Therapeutics Holdings (CRXT) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access CRXT Annual Balance Sheets →
The table below presents a historical view of Clarus Therapeutics Holdings's balance sheet, supporting analysis of financial position trends.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2022)
(Mar 31 2022) (Dec 31 2021) (Sep 30 2021) (Jun 30 2021)
Assets
Cash & cash equivalent19.17
Cash & Short-term Investments19.00
Accounts receivable8.71
Inventories16.81
Other Current Assets0.00
Prepaid Expense, Current AS4.20
Total Current Assets48.88
Equipment/Property/Plant Net0.06
Other Assets, Noncurrent0.00
Total Assets48.94
Liabilities
Accounts Payable, Current AC8.49
Accrued Liabilities, Current AC9.83
Notes Payable, Current NO40.51
Other Liabilities, Current0.00
Taxes Payable0.00
Deferred Revenue DE2.98
Total Current Liabilities61.81
Total Long-term Debt0.00
Derivative Liability, Noncurrent DE0.20
Other liabilities, Noncurrent0.00
Deferred Income Noncurrent-
Total Liabilities62.00
Stockholders' Equity
Common Stock Value-
Common Stock Value0.01
Additional Paid In Capital Common Stock334.15
Retained Earnings / Accumulated Deficit-347.22
Other Equity0.00
Common Stockholder's Equity-13.06
Non-controlling interests & other0.00
Total Stockholder's Equity-13.06
Liabilities & Stockholder's Equity48.94
4 historic quarters locked

Sign in to unlock the full Clarus Therapeutics Holdings balance sheet history.

About Clarus Therapeutics Holdings Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-22-224410

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.